VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | CPX-351 vs 7+3 in older high-risk AML patients

Thomas Prebet, MD, of the Yale School of Medicine, New Haven, CT, discusses the results of an exploratory analysis of the efficacy and safety of CPX-351 versus 7+3 in a Phase III study (NCT01696084) of older adults with high-risk/secondary acute myeloid leukemia (AML). Dr Prebet also highlights the importance of TP53 mutational status as a prognostic marker for success for patients in both treatment arms. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter